Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191685
Status:
COMPLETED
Last Update Posted:
2006-07-25
First Post:
2005-09-12
Brief Title:
Duloxetine in the Treatment of Melancholic Depression
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Duloxetine in the Treatment of Melancholic Depression An 8-Week Open-Label Dose Study
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose This study will allow investigators to mimic standard clinical practice During the first 2 weeks of treatment clinical evaluation of individual patient tolerability and efficacy will enable the dose of duloxetine to be adjusted Patients allocated to the Flex group may have their daily dose of duloxetine adjusted in the attempt to elicit a clinical response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1J-AY-HMCZ | None | None | None |